The Evicel Post-Authorization Surveillance Study

This study has been completed.
Sponsor:
Collaborator:
OMRIX Biopharmaceuticals
Information provided by (Responsible Party):
Ethicon, Inc.
ClinicalTrials.gov Identifier:
NCT01158261
First received: July 6, 2010
Last updated: July 16, 2014
Last verified: July 2014

July 6, 2010
July 16, 2014
June 2010
April 2014   (final data collection date for primary outcome measure)
Specific safety parameters [ Time Frame: Up to 4-weeks post-operatively ] [ Designated as safety issue: Yes ]
  • Incidence of graft occlusion
  • Incidence of adverse events potentially related to non-graft thrombotic events
  • Incidence of bleeding events
Not Provided
Complete list of historical versions of study NCT01158261 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Evicel Post-Authorization Surveillance Study
A Prospective, Single-Arm, Observational, Non-interventional Study for EVICEL ™ Fibrin Sealant (Human) When Used as an Adjunct to Haemostasis in Vascular Surgery

The objective of this non-interventional Post Authorisation Safety Surveillance (PASS) study is to observe the clinical safety performance of EVICEL when used as suture support for haemostasis in vascular surgery.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Subjects requiring elective vascular procedures

  • Peripheral Vascular Disease
  • Hemorrhage
Biological: EVICEL ™ Fibrin Sealant (Human)
Commercial Evicel
Other Name: Fibrin Sealant (Human)
Vascular Surgery Subjects
Intervention: Biological: EVICEL ™ Fibrin Sealant (Human)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
May 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects, 18 years or older, requiring elective, primary or repeat vascular procedures with at least one end-to-side anastomosis to the femoral artery or to an upper extremity artery
  • EVICEL Fibrin Sealant is used as an adjunct to obtain haemostasis at a target anastomosis/es
  • Subjects must be willing to and capable of participating in the study, and provide written informed consent

Exclusion Criteria:

  • Subjects with known intolerance to blood products
  • Subjects unwilling to receive blood products
  • Subjects with any intra-operative findings that may preclude the use of a fibrin sealant to control suture line anastomotic bleeding
  • Subject participating in another study with an investigational (pre-approved) drug or device within 30 days of surgery
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01158261
400-08-004
No
Ethicon, Inc.
Ethicon, Inc.
OMRIX Biopharmaceuticals
Study Director: Richard Kocharian, MD Ethicon, Inc.
Ethicon, Inc.
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP